<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03950830</url>
  </required_header>
  <id_info>
    <org_study_id>GCT-SK-006</org_study_id>
    <nct_id>NCT03950830</nct_id>
  </id_info>
  <brief_title>Disulfiram and Cisplatin in Refractory TGCTs.</brief_title>
  <acronym>DISGCT</acronym>
  <official_title>Phase II Study of Disulfiram and Cisplatin in Refractory TGCTs.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Slovakia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Slovakia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-randomized, open-label, single center trial to assess efficacy (as measured by overall&#xD;
      response rate (ORR) by RECIST 1.1 of disulfiram and cisplatin in patients with multiple&#xD;
      relapsed/refractory germ cell tumors (GCTs).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Germ-cell tumours (GCTs) are extraordinarily chemosensitive and resemble the clinical and&#xD;
      biological characteristics of a model for the cure of cancer. Nonetheless, a small proportion&#xD;
      of patients do not have a durable complete remission (CR) with initial chemotherapy. Only&#xD;
      20-40% of them will be cured with the use of platinum-containing standard-dose or high-dose&#xD;
      salvage chemotherapy with autologous stem cell transplantation (ASCT). Patients who fail to&#xD;
      be cured after second-line salvage therapy have an extremely poor prognosis and long term&#xD;
      survival had been documented in &lt;5%. Paclitaxel plus ifosfamide and cisplatin is considered&#xD;
      as a standard salvage chemotherapy in relapsed good prognosis GCTs, however, up to 40% of&#xD;
      favourable prognosis patients failed to achieve durable response to this combination, and&#xD;
      therefore new treatment strategies are warranted.&#xD;
&#xD;
      Previously, it was showed that cisplatin resistant TGCTs overexpress ALDH isoforms and&#xD;
      inhibition of ALDH activity by disulfiram is associated with reconstitution of cisplatin&#xD;
      sensitivity. Cisplatin-resistant TGCTs exhibited increased sensitivity to ALDH inhibitor&#xD;
      disulfiram in vitro. Although Disulfiram (Antabuse) is an approved drug to support the&#xD;
      treatment of chronic alcoholism, it may serve as an antitumor agent suitable for the drug&#xD;
      repurposing in combination therapy in order to inhibit ALDH activity thus overcoming a&#xD;
      cisplatin resistance in refractory TGCTs. Indeed, disulfiram in combination with cisplatin&#xD;
      very efficiently eradicated platinum-resistant NTERA-2 model spheroids and significantly&#xD;
      inhibited xenograft growth in vivo in our experimental system.&#xD;
&#xD;
      Based on aforementioned data, investigators suggest that there is strong rationale to inhibit&#xD;
      ALDH in TGCT. Investigators hypothesize that inactivation of ALDH by disulfiram recover&#xD;
      cisplatin sensitivity in patients with progressing or relapsing germ cell cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Non-randomized, open-label, single center trial to assess efficacy (as measured by overall response rate of disulfiram and cisplatin in patients with multiple relapsed/refractory germ cell tumors (GCTs).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>24 months</time_frame>
    <description>Overall response rate by RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Germ Cell Tumor</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 50mg/m2 day 1 and 2, every 3 weeks, Disulfiram 400mg daily, continuously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Disulfiram</intervention_name>
    <description>Disulfiram 400mg daily, continuously</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>Antabus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent .&#xD;
&#xD;
          2. Men aged 18 years or older.&#xD;
&#xD;
          3. ECOG performance status: 0-1.&#xD;
&#xD;
          4. Histologically confirmed extracranial primary germ cell cancer, seminoma, or&#xD;
             nonseminoma.&#xD;
&#xD;
          5. Rising serum markers (i.e., alpha-fetoprotein and human chorionic gonadotropin) on&#xD;
             sequential measurement or biopsy-proven unresectable germ cell cancer.&#xD;
&#xD;
          6. Multiple relapsed/refractory GCTs (at least 2 lines of previous chemotherapy and/or&#xD;
             patients relapsing after high-dose chemotherapy or for patients non fit enough for&#xD;
             high-dose chemotherapy.&#xD;
&#xD;
          7. Primary mediastinal GCTs in first relapse.&#xD;
&#xD;
          8. Patient's disease must not be amenable to cure with either surgery or chemotherapy in&#xD;
             the opinion of investigator.&#xD;
&#xD;
          9. RECIST 1.1 Measurable disease.&#xD;
&#xD;
         10. Adequate hematologic function defined by ANC &gt; 1500/mm3, platelet count &gt; 100 000/mm3&#xD;
             and hemoglobin level &gt; 9g/dl.&#xD;
&#xD;
         11. Adequate liver function defined by a total bilirubin level &lt; 1.5 ULN, and ALT, AST &lt; 3&#xD;
             ULN or &lt; 5 in case of liver metastases. For subjects with Gilbert's syndrome bilirubin&#xD;
             &gt; 1.5 Ã— ULN is allowed if no symptoms of compromised liver function are present.&#xD;
&#xD;
         12. Adequate renal function: measured or calculated (by Cockcroft formula) creatinine&#xD;
             clearance &gt; 50 ml/min. Cockcroft formula: CLcr = [(140-age) x weight (Kg)]/[72 x creat&#xD;
             (mg/dl)].&#xD;
&#xD;
         13. At least 4 weeks must have elapsed since the last radiotherapy and/or chemotherapy&#xD;
             before study entry.&#xD;
&#xD;
         14. At least 4 weeks must have elapsed since the last major surgery.&#xD;
&#xD;
         15. Complete recovery from prior surgery, and/or reduction of all adverse events from&#xD;
             previous systemic therapy or radiotherapy to grade 1.&#xD;
&#xD;
         16. Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who do not fit inclusion criteria.&#xD;
&#xD;
          2. Addiction to alcohol or drugs.&#xD;
&#xD;
          3. Other prior malignancy except successfully treated nonmelanoma skin cancer .&#xD;
&#xD;
          4. Need for metronidazole, warfarin and/or theophylline medication, the metabolism of&#xD;
             which is likely influenced by disulfiram.&#xD;
&#xD;
          5. Patients who are taking medications metabolized by cytochrome P450 2E1, including&#xD;
             chlorzoxazone or halothane and its derivatives.&#xD;
&#xD;
          6. Other concurrent approved or investigational anticancer treatment, including surgery,&#xD;
             radiotherapy, chemotherapy, biologic-response modifiers, hormone therapy, or&#xD;
             immunotherapy.&#xD;
&#xD;
          7. Female patients.&#xD;
&#xD;
          8. Patients infected by the Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
          9. Patients with other severe acute or chronic medical condition, or laboratory&#xD;
             abnormality that would impair, in the judgment of investigator, excess risk associated&#xD;
             with study treatment, or which, in judgment of the investigator, would make the&#xD;
             patient inappropriate for entry into this study.&#xD;
&#xD;
         10. Inability of oral intake, or drug absorbtion (e.g. malabsorption syndrome).&#xD;
&#xD;
         11. Hypersensitivity to any compound of the drug.&#xD;
&#xD;
         12. Sexually active men not using highly effective birth control if their partners are&#xD;
             women of child-bearing potential.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michal Mego, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Slovakia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michal Mego, Prof</last_name>
    <phone>+421-2-59378352</phone>
    <email>michal.mego@nou.sk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniela Svetlovska, Dr</last_name>
    <phone>+421-2-59378592</phone>
    <email>daniela.svetlovska@nou.sk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bratislava</city>
        <zip>83310</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Mego, Assoc. Prof</last_name>
      <phone>+421259378</phone>
      <phone_ext>366</phone_ext>
      <email>michal.mego@nou.sk</email>
    </contact>
    <contact_backup>
      <last_name>Jozef Mardiak, Prof</last_name>
      <phone>+421259378</phone>
      <phone_ext>108</phone_ext>
      <email>jozef.mardiak@nou.sk</email>
    </contact_backup>
    <investigator>
      <last_name>Jozef Mardiak, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michal Mego, Assoc. Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 12, 2019</study_first_submitted>
  <study_first_submitted_qc>May 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disulfiram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

